Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations.

ABSTRACT:

Rationale

Proline-glycine-proline (PGP), a neutrophil chemoattractant derived from the enzymatic breakdown of collagen, is elevated in sputum of patients with chronic obstructive pulmonary disease (COPD) and may contribute to disease progression. Whether sputum levels of PGP respond to therapy for COPD or predict outcomes is unknown.

Objectives

We conducted a study ancillary to a multicenter trial of the efficacy of azithromycin treatment for 1 year in preventing COPD exacerbations to test whether sputum levels of PGP were altered by treatment or associated with exacerbation frequency.

Methods

We collected remnant sputa from trial participants and assayed them in a blinded fashion for PGP, myeloperoxidase and matrix metalloproteinase (MMP)-9 and for the ability to gen

SUBMITTER: O'Reilly PJ 

PROVIDER: S-EPMC3884851 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature